Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
COMPLERA | Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate | HIV infection | List | Complete | ||
Yervoy | Ipilimumab | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Lucentis | Ranibizumab | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
Banzel | Rufinamide | Lennox-Gastaut syndrome | List with clinical criteria and/or conditions | Complete | ||
Edurant | Rilpivirine | HIV infection | List | Complete | ||
Trajenta | Linagliptin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
Targin | Oxycodone HCI / naloxone HCI | Pain, moderate to severe and relief of opioid-induced constipation | Do not list | Complete | ||
Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete |